Get the Stockscreener App
1.33
0.75%
-0.01
After Hours:
1.33
Mustang Bio Inc stock is traded at $1.33, with a volume of 32,170.
It is down -0.75% in the last 24 hours and down -6.34% over the past month.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
See More
Previous Close:
$1.34
Open:
$1.34
24h Volume:
32,170
Relative Volume:
0.17
Market Cap:
$3.75M
Revenue:
-
Net Income/Loss:
$-23.42M
P/E Ratio:
-0.0171
EPS:
-78
Net Cash Flow:
$-16.67M
1W Performance:
-0.75%
1M Performance:
-6.34%
6M Performance:
-87.75%
1Y Performance:
-93.07%
1-Day Range:
$1.27
$1.34
1-Week Range:
$1.27
$1.40
52-Week Range:
$1.15
$65.00
Mustang Bio Inc Stock (MBIO) Company Profile
Name
Mustang Bio Inc
Sector
Industry
Phone
(781) 652-4500
Address
377 PLANTATION STREET, WORCESTER, NY
Compare MBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBIO
Mustang Bio Inc
|
1.33 | 3.75M | 0 | -23.42M | -16.67M | -78.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Mustang Bio Inc Stock (MBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-21 | Initiated | BTIG Research | Buy |
| Oct-02-20 | Initiated | B. Riley FBR | Buy |
| Nov-20-19 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-19 | Initiated | H.C. Wainwright | Buy |
| Jun-21-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Initiated | Oppenheimer | Outperform |
View All
Mustang Bio Inc Stock (MBIO) Latest News
Mustang Bio stock hits 52-week low at $1.20 amid sharp decline - Investing.com Canada
Mustang Bio stock hits 52-week low at $1.20 amid sharp decline By Investing.com - Investing.com South Africa
Mustang Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Mustang Bio Inc. (MBIO) reports earnings - Quartz
MUSTANG BIO, INC. SEC 10-K Report - TradingView
Mustang Bio stock plunges to 52-week low of $1.35 By Investing.com - Investing.com Australia
Mustang Bio stock plunges to 52-week low of $1.35 - Investing.com India
Fortress Biotech partners with Partex for AI-driven drug discovery - Investing.com
Car T Cell Therapy Market Demand, Statistics, Future Growth and Outlook 2025-2032 | Mustang Bio, Fate Therapeutics - openPR
Mustang Bio stock plunges to 52-week low of $1.43 By Investing.com - Investing.com Australia
Mustang Bio stock plunges to 52-week low of $1.43 - Investing.com India
Mustang Bio Stock Price, Quotes and Forecasts | NASDAQ:MBIO - Benzinga
Petri Dish: Biotech leaves Worcester; Novo Nordisk, Eli Lilly partnerships - The Business Journals
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement - The Manila Times
Mustang Bio Regains Nasdaq Compliance, Secures Position For Cell Therapy Advancements - Nasdaq
Mustang Bio meets Nasdaq’s equity listing requirements By Investing.com - Investing.com Canada
Mustang Bio meets Nasdaq’s equity listing requirements - Investing.com India
Mustang Bio, Inc. Regains Compliance with Nasdaq Capital Market Listing Requirements - Nasdaq
Mustang Bio Overcomes Delisting Threat: What This Nasdaq Compliance Means for Investors - StockTitan
BRIEF—Mustang Bio sells assets; focuses on MB-109, MB-108 and MB-101 - The Pharma Letter
Mustang Bio (MBIO) Projected to Post Earnings on Monday - Defense World
Mustang Bio stock plunges 29% on lease termination news - MSN
Mustang Bio stock plunges to 52-week low at $2 By Investing.com - Investing.com Australia
Mustang Bio stock plunges to 52-week low at $2 - Investing.com
Mustang Bio exits Worcester facility, sells assets to AbbVie By Investing.com - Investing.com Australia
Mustang Bio stock plunges 29% on lease termination news (MBIO:NASDAQ) - Seeking Alpha
Mustang Bio exits lease for Massachusetts facility, divests equipment - TipRanks
Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility -February 27, 2025 at 05:49 pm EST - Marketscreener.com
Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility - MarketWatch
Mustang Bio exits Worcester facility, sells assets to AbbVie - Investing.com
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility - The Manila Times
Can Mustang Bio's $3M Financial Boost From Facility Exit Revitalize Its Cancer Therapy Pipeline? - StockTitan
Mustang Bio secures shareholder nod for warrant share issuance By Investing.com - Investing.com South Africa
Mustang Bio secures shareholder nod for warrant share issuance - Investing.com India
CI Financial Corp (CIX:CA): Stock Forecast and Q4 2024 Earnings Report - The Globe and Mail
Mustang Bio sells assets and ends lease with AbbVie By Investing.com - Investing.com India
Mustang Bio stock plunges to 52-week low of $2.6 amid sharp decline - Investing.com Nigeria
Mustang Bio sells assets and ends lease with AbbVie - MSN
Mustang Bio Inc Stock (MBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):